Ulinastatin reduces postoperative bleeding and red blood cell transfusion in patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis

Medicine (United States)

Volumn 99, Issue 7, 2020, Pages

  Yao, Yun Tai ^a   Fang, Neng Xin ^a   Liu, Ding Hua ^b   Li, Li Huan ^a  

^a FUWAI HOSPITAL   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Bleeding; Cardiac surgery; Meta analysis; Transfusion; Ulinastatin

Indexed keywords

ANTITHROMBIN; D DIMER; FIBRINOGEN; FRESH FROZEN PLASMA; HEMOGLOBIN; HEPARIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; POLYMORPHONUCLEAR ELASTASE; PROTAMINE; THROMBOCYTE CONCENTRATE; TUMOR NECROSIS FACTOR; ULINASTATIN; UNCLASSIFIED DRUG; GLYCOPROTEIN; TRYPSIN INHIBITOR;

BLOOD CLOTTING TEST; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; HEART SURGERY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; META ANALYSIS; NEUTROPHIL COUNT; OPERATIVE BLOOD LOSS; PLATELET COUNT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; BLOOD CLOTTING; BLOOD TRANSFUSION; THROMBOCYTE;

BLOOD COAGULATION; BLOOD PLATELETS; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; GLYCOPROTEINS; HUMANS; POSTOPERATIVE HEMORRHAGE; TRYPSIN INHIBITORS;

EID: 85079334097     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000019184     Document Type: Review

References (62)

1. Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31.
2. Wang X, Zheng Z, Ao H, et al. A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China. J Thorac Cardiovasc Surg 2009;138:897-903.
3. Pugia MJ, Lott JA. Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clin Chem Lab Med 2005;43:1-6.
4. Pugia MJ, Valdes RJr, Jortani SA. Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement. Adv Clin Chem 2007;44:223-45.
5. He S, Lin K,Ma R, et al. Effect of the urinary tryptin inhibitor ulinastatin on cardiopulmonary bypass-related inflammatory response and clinical outcomes: a meta-analysis of randomized controlled trials. Clin Ther 2015;37:643-53.
6. Zhang Y, Zeng Z, Cao Y, et al. Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for China and Japan. PLoS One 2014;9:e113973.
7. He QL, Zhong F, Ye F, et al. Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Biomed Res Int 2014;2014:630835.
8. Okida M, Masako O, Maruya H, et al. Intraoperative changes in blood coagulation and the effectiveness of ulinastatin during liver resection. J Anesth 1991;5:43-7.
9. Ji HW, Chen L. Effects of ulinastatin on coagulation and platelet function in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Zhonghua Yi Xue Za Zhi 2009;89:175-8.
10. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
11. Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane bias methods group; cochrane statistical methods group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
12. Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 1999;20:448-52.
13. O'Rourke K. Mixed Means and Medians: A Unified Approach to Deal With Disparate Outcome Summaries. Proceedings of the 4th Symposium on Systematic Reviews: Pushing the Boundaries. Oxford: Cochrane Methodol Register; 2002. 49.
14. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
15. Pang XY, Fang CC, Chen YY, et al. Effects of ulinastatin on perioperative inflammatory response and pulmonary function in cardiopulmonary bypass patients. Am J Ther 2016;23:e1680-9.
16. Nakanishi K, Takeda S, Sakamoto A, et al. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006;34:1351-7.
17. Xu CE, Zou CW, Zhang MY, et al. Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after cardiopulmonary bypass under deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth 2013;27:479-84.
18. Kim NY, Shim JK, Bang SO, et al. Effects of ulinastatin on coagulation in high-risk patients undergoing off-pump coronary artery bypass graft surgery. Korean J Anesthesiol 2013;64:105-11.
19. Park JB, Kim SH, Lee SA, et al. Effects of ulinastatin on postoperative blood loss and hemostasis in atrioventricular valve surgery with cardiopulmonary bypass. Korean J Thorac Cardiovasc Surg 2013;46: 185-91.
20. Song JE, Kang WS, Kim DK, et al. The effect of ulinastatin on postoperative blood loss in patients undergoing open heart surgery with cardiopulmonary bypass. J Int Med Res 2011;39:1201-10.
21. Bingyang J, Jinping L, Mingzheng L, et al. Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response. J Cardiovasc Surg 2007;48:497-503.
22. Chen TT, Liu JD, Wang G, et al. Combined treatment of ulinastatin and tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery. Heart Surg Forum 2013;16:E38-47.
23. Qiu Y, Lin J, Yang Y, et al. Lack of efficacy of ulinastatin therapy during cardiopulmonary bypass surgery. Chin Med J 2015;128:3138-42.
24. Wang GY, Ji BY, Liu NN, et al. Effect of ulinastatin on thrombin and platelet activation in the patients during off-pump coronary artery bypass graft surgery. Chin J ECC 2010;8: 100-2, 21.
25. Zhai YJ, Wang XL. The protection of ulinastatin and aprotinin on blood fibrinolytic system during cardiopulmonary bypass. Chin J ECC 2004;2:84-6.
26. Yang WH, Zhang H, Shang BJ. Ulinastatin and aprotinin to blood protection of operation on vessels of heart. Med Recapitulate 2010;16: 2374-6.
27. Shi ZR, Jiang ZF, Li JD, et al. Protective effects of ulinastatin on thrombocytic function in infants and children undergoing open heart surgery under cardiopulmonary bypass. Jiangsu Med J 2008;34:795-7.
28. Shu YZ, Xiang DK, Zhou T. Effects of ulinstatin on blood coagulative function at cardiopulomonary bypass patients. Guizhou Med J 2003;27:883-4.
29. Tan RD, Liang RQ, Chen HM. The effect of ulinastatin and reptilase on safeguard of blood in patients undergoing cardiac surgery under extracorporeal circulation. Mod Hosp 2011;11:26-8.
30. Le HB, Zhang YQ, Zhang BJ. Platelet protective effect of ulinastatin during cardiopulmonary bypass. Zhejiang Med 2005;27:84-6.
31. Zhang BJ, Zhang YQ, Le HB, et al. The effects of ulinastatin and tranexamic acid on D-dimer during cardiopulmonary bypass. J Cardiovasc Dis 2004;23:32-3.
32. Jin XG, Fang GA, Liu B, et al. Effects of ulinastatin and tranexamic acid on platelet during cardiopulmonary bypass. Chin Pharm J 2005;993-5:998.
33. Yu JG, Shuai XJ, Zhou GL, et al. The effect of ulinastatin on blood fibrinolytic system and platelet function during cardiopulmonary bypass. Chin J Anesthesiol 2003;23:7-10.
34. Shi J, Li LH. Effects of Ulinastatin and Tranexamic Acid on Hemostasis and Inflammatory Mediators in Cardiac Surgical Procedures (Doctorate Thesis). Beijing, China: Peking Union Medical College; 2010.
35. Liu MZ, Ji BY, Wang GY, et al. Effects of urinary protease inhibitor on activated leukocytes and platelets during extracorporeal circulation. Chin J ECC 2008;6:75-7.
36. Ji BY, Long C. The proactive effect of ulinastatin on the organs during extracorporeal circulation. Chin J Clin Thorac Cardiovasc Surg 2002;9:51-3.
37. Chen HL, Li H. The effect of Ulinastatin combined with hemocoagulase on coagulation function in patients undergoing cardiac surgery with cardiopulmonary bypass. Chin J Mod Drug Appl 2010;4:153-4.
38. Lu T, He ZF. The effect of large dose Ulinastatin on coagulation function in patients undergoing cardiac surgery with cardiopulmonary bypass. Xibei Yaoxue Zazhi 2004;19:180-1.
39. Mao GZ, Ji H,WuLG, et al. Effects of tranexamic acid and Ulinastatin on inflammatory cytokines coagulation function and cognitive function in patients with cardiac surgery. Chin J Rational Drug Use 2017;14:10-3.
40. Wang ZL. Comparison of the effects among tranexamic acid, Ulinastatin and aprotinin in coronary surgical patients. Heibei Med 2014;36: 2214-6.
41. Wu T, Wen QX. Study on the effects of ulinastatin plus tranexamic acid and aprotinin on cardiopulmonary bypass. Tianjin Med J 2005;33: 767-9.
42. Ren TY, Yang XW,MaY, et al.Myocardial protective effect of ulinastatin against ischemia/reperfusion injury during open heart surgery with cardiopulmonary bypass. Zhonghua Yi Xue Za Zhi 2003;83:1391-3.
43. Wang GY, Qiu HB, Zhan SG, et al. Protection of ulinastatin against myocardial injury induced by off-pump coronary artery bypass graft surgery: report of 24 cases. Zhonghua Yi Xue Za Zhi 2007;87:2502-4.
44. Gao L, Yang BX, Li F, et al. Advantages of ulinastatin in off-pump coronary artery bypass surgery. Chin J New Drugs 2005;14:470-2.
45. Chang KQ, Yang DX, Wang GY, et al. Effects of large dose of ulinastatin on coagulation-fibrinolysis system during normothermia extracorporeal circulation in rabbits. Chin J ECC 2008;6:247-50.
46. Chang KQ, Yang DX, Wang GY, et al. Effects of different doses of ulinastatin on coagulation-fibrinolysis system during normothermia cardiopulmonary bypass in rabbits. Mol Cardio Chin 2009;9:310-3.
47. Chang KQ, Yang DX, Wang GY, et al. Effects of large dose of ulinastatin on coagulation-fibrinolysis system during normothermia cardiopulmonary bypass in rabbits. Chin Mol Cardio 2009;9:310-3.
48. Ikeda U, Yamamoto K, Shimada K. Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy. Clin Cardiol 1997;20:7-10.
49. Jimenez JJ, Iribarren JL, Lorente L, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care 2007;11:R117.
50. Bønding Andreasen J, Hvas AM, Ravn HB. Marked changes in platelet count and function following pediatric congenital heart surgery. Paediatr Anaesth 2014;24:386-92.
51. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004;47:305-14.
52. Manfredi AA, Rovere-Querini P, Maugeri N. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol 2010;17:3-8.
53. Despotis GJ, Avidan MS, Hogue CWJr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001;72:S1821-31.
54. Nakatani K, Takeshita S, Tsujimoto H, et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001;69:241-7.
55. Shu H, Liu K, He Q, et al. Ulinastatin, a protease inhibitor, may inhibit allogeneic blood transfusion-associated pro-inflammatory cytokines and systemic inflammatory response syndrome and improve postoperative recovery. Blood Transfus 2014;12 Suppl 1:s109-18.
56. Nishiyama T, Hanaoka K. Do the effects of a protease inhibitor, ulinastatin, on elastase release by blood transfusion depend on interleukin 6? Crit Care Med 2001;29:2106-10.
57. Nishiyama T, Aibiki M, Hanaoka K. The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Anesth Analg 1996;82: 108-12.
58. Nishiyama T, Hanaoka K. Hemolysis in stored red blood cell concentrates: modulation by haptoglobin or ulinastatin, a protease inhibitor. Crit Care Med 2001;29:1979-82.
59. Liu DH, Yao YT, Li LH, et al. Effects of ulinastatin on in vitro storage lesions of human red blood cells. Clin Lab 2017;63:833-8.
60. Chen Q, Hu C, Liu Y, et al. Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: a randomized, double-blind, placebo-controlled, ascendingdose study. PLoS One 2017;12:e0177425.
61. Jönsson-Berling BM, Ohlsson K. Distribution and elimination of intravenously injected urinary trypsin inhibitor. Scand J Clin Lab Invest 1991;51:549-57.
62. Enzan K, Mitsuhata H, Masaki Y, et al. Effects of ulinastatin on granulocyte elastase and fibronectin in patients undergoing cardiopulmonary bypass. Masui 1991;40:1625-31.